Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.

The first list of 8 companies that could reach Dividend King status in coming years. These companies provide investors a wide range of starting dividend yields and growth histories. It's possible one or more of these companies do not attain Dividend King status.

Medical device maker Medtronic said on Wednesday ​it plans to ‌acquire privately held SPR Therapeutics for about $650 million in cash, expanding ​its portfolio of ​treatments for chronic pain.

Acquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferers GALWAY, Ireland, May 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650 million for all the outstanding equity in SPR.

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

Both offer dividends that yield well above the current S&P 500 index average of 1.1%. The first company is already a Dividend King, while the other is very close to joining that celebrated group.

The latest trading day saw Medtronic (MDT) settling at $77.32, representing a +1.54% change from its previous close.

With a 3.7% yield and 48 consecutive annual dividend increases, this medical device maker will interest long-term dividend investors. Value investors, meanwhile, will appreciate the fact that the stock's P/S, P/E, and P/B ratios are all below their five-year averages.

Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics.

In the closing of the recent trading day, Medtronic (MDT) stood at $74.54, denoting a -2.11% move from the preceding trading day.